Lupin signs an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of around USD 75 million, which is more than 600 crores in Indian rupees.
Inhalation portfolio of Lupin expands in the US with these acquisitions of Brovana and Xopenex HFA.
- Read more about Lupin acquires two inhalation brands from Sunovion over 600 crores
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/lupin-acquires-two-inhalation-brands-from-sunovion-over-600-crores
No comments:
Post a Comment